A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Inclusion Criteria:
Exclusion Criteria:
rribeiro@eyepoint.bio833-393-7646
Bakersfield, California 93309, United States
info@eyepointpharma.com1.833.393.7646
Mountain View, California 94040, United States
Sacramento, California 95825, United States
St. Petersburg, Florida 33711, United States
Baltimore, Maryland 21287, United States
Asheville, North Carolina 28803, United States
Winston-Salem, North Carolina 27103, United States
Abilene, Texas 79606, United States
Banská Bystrica, Slovakia
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com833-393-7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com833-393-7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.8
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com833-393-7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646